Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Taysha Gene Therapies (TSHA) Accumulated Expenses: 2022-2025

Historic Accumulated Expenses for Taysha Gene Therapies (TSHA) over the last 4 years, with Sep 2025 value amounting to $17.7 million.

  • Taysha Gene Therapies' Accumulated Expenses rose 40.45% to $17.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $17.7 million, marking a year-over-year increase of 40.45%. This contributed to the annual value of $12.9 million for FY2024, which is 4.71% up from last year.
  • According to the latest figures from Q3 2025, Taysha Gene Therapies' Accumulated Expenses is $17.7 million, which was up 45.73% from $12.2 million recorded in Q2 2025.
  • Taysha Gene Therapies' Accumulated Expenses' 5-year high stood at $26.6 million during Q1 2022, with a 5-year trough of $10.8 million in Q1 2025.
  • Over the past 3 years, Taysha Gene Therapies' median Accumulated Expenses value was $12.9 million (recorded in 2024), while the average stood at $14.0 million.
  • Per our database at Business Quant, Taysha Gene Therapies' Accumulated Expenses plummeted by 39.51% in 2024 and then skyrocketed by 40.45% in 2025.
  • Over the past 4 years, Taysha Gene Therapies' Accumulated Expenses (Quarterly) stood at $18.3 million in 2022, then slumped by 32.83% to $12.3 million in 2023, then climbed by 4.71% to $12.9 million in 2024, then spiked by 40.45% to $17.7 million in 2025.
  • Its Accumulated Expenses stands at $17.7 million for Q3 2025, versus $12.2 million for Q2 2025 and $10.8 million for Q1 2025.